Cargando…

Dysregulation of the Sirt5/IDH2 axis contributes to sunitinib resistance in human renal cancer cells

Sunitinib (Sun), a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, is the standard first‐line treatment against advanced clear cell renal cell carcinoma (RCC), but resistance to therapy is inevitable. Reactive oxygen species production is associated with sensitivity to chem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meng, Liang, Chen, Deqiang, Meng, Gaopei, Lu, Li, Han, Chenggang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931237/ https://www.ncbi.nlm.nih.gov/pubmed/33455080 http://dx.doi.org/10.1002/2211-5463.13090

Ejemplares similares

circRNA DENND1B inhibits tumorigenicity of clear cell renal cell carcinoma via miR-122-5p/TIMP2 axis
por: Chen, Deqiang, et al.
Publicado: (2022)

Dysregulation of the SIRT1/OCT6 Axis Contributes to Environmental Stress-Induced Neural Induction Defects
por: Li, Guoping, et al.
Publicado: (2017)

Sunitinib resistance in renal cell carcinoma
por: Morais, Christudas
Publicado: (2014)

TFE3‐PD‐L1 axis is pivotal for sunitinib resistance in clear cell renal cell carcinoma
por: Guo, Xudong, et al.
Publicado: (2020)

Dysregulation of the miR-34a-SIRT1 axis inhibits breast cancer stemness
por: Ma, Wei, et al.
Publicado: (2015)

Sunitinib-induced cardiac hypertrophy and the endothelin axis
por: Sourdon, Joevin, et al.
Publicado: (2021)

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib
por: Serova, Maria, et al.
Publicado: (2016)

Overexpression of miR-15b Promotes Resistance to Sunitinib in Renal Cell Carcinoma
por: Lu, Lu, et al.
Publicado: (2019)

A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression
por: Liu, Wentao, et al.
Publicado: (2022)

The SIRT7-mediated deacetylation of CHD1L amplifies HIF-2α-dependent signal that drives renal cell carcinoma progression and sunitinib resistance
por: He, Hongchao, et al.
Publicado: (2023)

Sunitinib for advanced renal cell cancer
por: Coppin, Chris
Publicado: (2008)

Transgelin Contributes to a Poor Response of Metastatic Renal Cell Carcinoma to Sunitinib Treatment
por: Bouchalova, Pavla, et al.
Publicado: (2021)

Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway
por: Gao, Yongqian, et al.
Publicado: (2016)

The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer
por: Azijli, Kaamar, et al.
Publicado: (2015)

Metabolomic Analysis to Elucidate Mechanisms of Sunitinib Resistance in Renal Cell Carcinoma
por: Sato, Tomonori, et al.
Publicado: (2020)

Enhanced YB1/EphA2 axis signaling promotes acquired resistance to sunitinib and metastatic potential in renal cell carcinoma
por: Ruan, Hailong, et al.
Publicado: (2020)

Circular RNA Eps15-homology domain-containing protein 2 induce resistance of renal cell carcinoma to sunitinib via microRNA-4731-5p/ABCF2 axis
por: Li, Wen, et al.
Publicado: (2022)

Establishment of a non-small-cell lung cancer-liver metastasis patient-derived tumor xenograft model for the evaluation of patient-tailored chemotherapy
por: Yang, Xue, et al.
Publicado: (2019)

IDH1 mutations induce organelle defects via dysregulated phospholipids
por: Lita, Adrian, et al.
Publicado: (2021)

Insulin Resistance and Pellino-1 Mediated Decrease in the Activities of Vasodilator Signaling Contributes to Sunitinib-Induced Hypertension
por: Liu, Yang, et al.
Publicado: (2021)

A Dysregulation of the Prolactin/Vasoinhibin Axis Appears to Contribute to Preeclampsia
por: Lenke, Livia, et al.
Publicado: (2020)

Elucidating mechanisms of sunitinib resistance in renal cancer: an integrated pathological-molecular analysis
por: Butz, Henriett, et al.
Publicado: (2017)

The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance
por: Lin, Harrison Sicheng, et al.
Publicado: (2022)

Nephrotic Syndrome and Acute Renal Failure Apparently Induced by Sunitinib
por: Chen, Ying-Shou, et al.
Publicado: (2009)

Correction: Enhanced YB1/EphA2 axis signaling promotes acquired resistance to sunitinib and metastatic potential in renal cell carcinoma
por: Ruan, Hailong, et al.
Publicado: (2022)

AIM2 promotes renal cell carcinoma progression and sunitinib resistance through FOXO3a-ACSL4 axis-regulated ferroptosis
por: Wang, Qi, et al.
Publicado: (2023)

SIRT3 and GCN5L regulation of NADP+- and NADPH-driven reactions of mitochondrial isocitrate dehydrogenase IDH2
por: Smolková, Katarína, et al.
Publicado: (2020)

Dysregulation of MiR-144-5p/RNF187 Axis Contributes To the Progression of Colorectal Cancer
por: Gao, Zhuo, et al.
Publicado: (2022)

Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study
por: Lu, Haohao, et al.
Publicado: (2023)

A dysregulated bile acid-gut microbiota axis contributes to obesity susceptibility
por: Wei, Meilin, et al.
Publicado: (2020)

miR-96-5p targets PTEN to mediate sunitinib resistance in clear cell renal cell carcinoma
por: Park, Sang Eun, et al.
Publicado: (2022)

Exosomal IDH1 increases the resistance of colorectal cancer cells to 5-Fluorouracil
por: Yang, Hao, et al.
Publicado: (2021)

Characterisation of the Morphological, Functional and Molecular Changes in Sunitinib-Resistant Renal Cell Carcinoma Cells
por: Kamli, Hossam, et al.
Publicado: (2018)

AB071. The role of long non-coding RNAs in sunitinib resistance of renal cancer
por: Qu, Le, et al.
Publicado: (2017)

QPCT regulation by CTCF leads to sunitinib resistance in renal cell carcinoma by promoting angiogenesis
por: Zhao, Tangliang, et al.
Publicado: (2021)

Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells
por: Rausch, Magdalena, et al.
Publicado: (2021)

Sunitinib and other targeted therapies for renal cell carcinoma
por: Powles, T, et al.
Publicado: (2011)

The complexity of sunitinib dosing in renal cell cancer patients
por: Desar, Ingrid M.E., et al.
Publicado: (2012)

Sunitinib re-challenge in advanced renal-cell carcinoma
por: Porta, C, et al.
Publicado: (2014)

Key sunitinib‐related biomarkers for renal cell carcinoma
por: Peng, Yun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a4i3vp1oj7rt94ln719eef44np